Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,003.00-1.37%ETH$2,254.70-0.65%GOLD$3,963.20-0.16%OIL$96.91+0.47%
Smart Investors Daily
SID Premium
SL

NASDAQ · SLDB

Solid Biosciences Inc.

Healthcare · Biotechnology

$6.20

Down-$0.20 (-3.23%)

Updated Nov 3, 2026, 12:55 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
458.1M
P/E ratio
-3.32
Dividend yield
0.00%
52-week range
$5.39 – $11.45
Volume
873.12K
Avg. volume
1.15M

Price performance · SLDB

SLDB price history

1M range · 0 trading sessions · Daily adjusted prices

SLDB does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SLDB news

The latest Smart Investors Daily articles mentioning SLDB.

Stock researchCompany · Overview

SLDB research

Overview

Company profile and research snapshot.

Company profile

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.67
Implied upside
—
Analysts
19
SLDB recent ratings
DateFirmRatingTarget
Oct 15, 2026UBSBuy—
Sep 16, 2026RBC CapitalOutperform—
Sep 14, 2026HC Wainwright & Co.Buy—
Aug 27, 2026Cantor FitzgeraldOverweight—
Aug 21, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia

- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five participants have been dosed in the ongoing Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of Octob

Yahoo · Oct 20, 2026

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. The accepted abstracts span multiple areas of gene therapy resear

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By